Burcon Nutrascience Corporation (TSX: BU) is progressing from commissioning into early utilization at its Galesburg facility, with increasing customer volume driving better fixed-cost absorption, according to an update from Stonegate Capital Partners. The company completed commissioning and launched commercial production across its Peazazz pea protein, Puratein C canola protein, and FavaPro fava protein lines during fiscal year 2026.
Revenue rose sequentially to $0.83 million in the fourth quarter of fiscal 2026 from $0.74 million in the third quarter. Management indicated that current-quarter sales were tracking toward approximately 50% sequential growth based on April and May activity. The company also set a new production record, with daily output roughly 60% above the January through March levels. As volume builds, the margin opportunity is expected to come from better utilization, a steadier production cadence, and start-up costs moving out of the run-rate cost structure, rather than from pricing alone.
Customer traction is broadening, with more than 30 purchasing customers and over 200 active projects across pea, canola, and fava applications. Funding supports the Galesburg scale-up, with $6.9 million completed, $3.0 million undrawn, and management targeting $10 million of calendar year 2026 sales. For more details, view the full announcement here.
The transition from commissioning to utilization ramp is significant for Burcon as it moves toward commercial viability in the plant-based protein market. The increasing customer volume and production records indicate growing demand for its pea, canola, and fava proteins. The company's ability to absorb fixed costs more efficiently as output rises could improve margins, which is critical for competing in the crowded alternative protein space. Achieving a 50% sequential sales growth in the current quarter suggests strong momentum, though sustained execution will be key to reaching the $10 million sales target for calendar 2026.
For the industry, Burcon's progress highlights the challenges and opportunities in scaling up novel protein production. The company's focus on multiple protein sources—pea, canola, and fava—positions it to serve various market segments, but the capital-intensive nature of production requires continued funding. The undrawn $3.0 million provides some buffer, but achieving profitability will depend on maintaining production efficiency and securing more customers.
Stonegate Capital Partners, a leading capital markets advisory firm, provided the update. Their affiliate, Stonegate Capital Markets (member FINRA), offers investment banking services. Investors and industry watchers will be monitoring Burcon's ability to sustain growth and manage costs as it ramps utilization at Galesburg.
